Trevi Therapeutics (TRVI) Income from Continuing Operations (2018 - 2026)
Trevi Therapeutics' (TRVI) quarterly Income from Continuing Operations came in at 13192000.0 in Q1 2026, down 27.58% year-on-year from 18216517.09 in Q1 2025, and down 58.73% quarter-over-quarter from 8311000.0 in Q4 2025.
Trevi Therapeutics (TRVI) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 13192000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 27.58% year-over-year to 13192000.0 in Q1 2026; TTM through Mar 2026 was 45606000.0, a 3.58% increase from a year earlier, with the FY2025 full-year figure at 42754000.0, up 10.67% from the prior year.
- Income from Continuing Operations declined to 13192000.0 in Q1 2026 per TRVI's latest filing, from 8311000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 5505000.0 in Q4 2022 and bottomed at 13242000.0 in Q3 2024.
- The 5-year median for Income from Continuing Operations is 8311000.0 (2025), against an average of 9530705.88.
- Across the five-year window, Income from Continuing Operations surged 35.39% in 2022 and tumbled 72.88% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 5505000.0 in 2022, then slumped by 42.07% to 7821000.0 in 2023, then plunged by 45.29% to 11363000.0 in 2024, then increased by 26.86% to 8311000.0 in 2025, then slumped by 58.73% to 13192000.0 in 2026.
- Per Business Quant, the three latest TRVI Income from Continuing Operations figures stand at 13192000.0 (Q1 2026), 8311000.0 (Q4 2025), and 11802000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Trevi Therapeutics | 2.54 Bn | 2.54 Bn | - | -13.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.19 Mn |
| Dec 31, 2025 | -8.31 Mn |
| Sep 30, 2025 | -11.80 Mn |
| Jun 30, 2025 | -12.30 Mn |
| Mar 31, 2025 | -10.34 Mn |
| Dec 31, 2024 | -11.36 Mn |
| Sep 30, 2024 | -13.24 Mn |
| Jun 30, 2024 | -12.35 Mn |
| Mar 31, 2024 | -10.90 Mn |
| Dec 31, 2023 | -7.82 Mn |
| Sep 30, 2023 | -7.70 Mn |
| Jun 30, 2023 | -7.15 Mn |
| Mar 31, 2023 | -6.40 Mn |
| Dec 31, 2022 | -5.51 Mn |
| Sep 30, 2022 | -8.27 Mn |
| Jun 30, 2022 | -8.05 Mn |
| Mar 31, 2022 | -7.33 Mn |
| Dec 31, 2021 | -8.52 Mn |
| Sep 30, 2021 | -7.26 Mn |
| Jun 30, 2021 | -9.79 Mn |